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With the expanding use of targeted agents for the treatment of 
advanced or metastatic renal cell carcinoma (RCC), the prognosis 
for this condition is shifting toward that of a chronic treatable 
disease. The treatment of patients for increasingly long periods of 
time with these agents has raised new challenges related to the 
management of the associated adverse events (AEs). Six targeted 
agents for the treatment of advanced RCC are now approved and in 
clinical use: the tyrosine kinase inhibitors (TKIs) sunitinib and 
pazopanib, the multikinase inhibitor sorafenib (often also referred 
to as a TKI and grouped accordingly for the purpose of this review), 
the anti–vascular endothelial growth factor (VEGF) monoclonal 
antibody bevacizumab, and the mammalian target of rapamycin 
(mTOR) inhibitors temsirolimus and everolimus (1–6). These 
agents present a range of AEs for patients and their health-care 
providers to manage. A growing number of articles are being pub-
lished offering advice on AE monitoring and management with no 
clear consensus recommendations. Clearly, the prevention, early 
detection, and optimal management of AEs are key to maintaining 
patients on each individual treatment for as long as possible. In 
addition, minimizing the impact of toxicities on patients’ health 
should increase the likelihood that they will be able to tolerate 
additional lines of treatment. However, with so many suggested mon-
itoring strategies, the risk is that patients will become subjected to 
a barrage of assessments that are not always necessary or beneficial.
The objectives of this review were to assess critically the litera-
ture on AE monitoring and management during treatment of 
advanced RCC with targeted agents, to identify where there are 
adequate supporting data, where supporting data are lacking, and 
where further study is needed, and to provide physicians with spe-
cific practical guidance on essential monitoring and management 
that should be undertaken when using targeted agents.
Methods
An English language search of literature published between 
January 2007 and March 2011 was carried out using therapy-
related, disease-related, and AE-related search terms, including 
the names of approved targeted therapies for renal cancer, all com-
monly used terms for RCC and a wide variety of terms associated 
with toxicity such as cardiotoxicity, hepatotoxicity, skin reaction, 
and nephrotoxicity. Databases searched were PubMed/Medline, 
Embase, Biosis, Derwent Drug File, and Science Citation Index 
(search dates were January 2007 to March 2011). In particular, the 
Science Citation Index database covers abstracts from the American 
Society of Clinical Oncology (ASCO) annual meeting and genito-
urinary cancers symposia. ASCO abstracts from January 2010 to 
March 2011 were hand searched, as were European Society of 
Medical Oncology congress abstracts. Original articles describing 
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monitoring and management strategies were included. Additional 
information was taken from the European summary of product 
characteristics for each of the agents under consideration. 
Monitoring and management strategies for groups of AEs were 
reviewed by at least two co-authors, and any specific recommenda-
tions were approved by all co-authors. A total of 107 articles were 
identified that describe a large number of different investigations 
for monitoring AEs and interventions for AE management.
Overview of AE Profiles of Targeted Agents
The European summaries of product characteristics (1–6) list com-
monly reported AEs for six currently licensed targeted agents 
(sorafenib, sunitinib, pazopanib, bevacizumab + interferon alpha 
[IFN-a], temsirolimus, and everolimus) (Table 1) as well as poten-
tially serious or life-threatening AEs (Table 2). It should be 
acknowledged that safety data reported by the European sum-
maries of product characteristics tend to focus on registration 
trials. Thus, some AEs reported in other data sources may not be 
included, but focusing on the European summary of product char-
acteristics ensured a consistent, balanced approach. Many of the 
most common AEs are seen during treatment with all the targeted 
agents (although they may vary in severity from one agent to 
another), whereas others are more specific to one class of agent or 
to individual agents. The risk of hypothyroidism, for example, is 
high for sunitinib but also associated with the use of other drugs.
Tyrosine Kinase Inhibitors
In general, the TKIs (sorafenib, sunitinib, pazopanib) are most 
commonly associated with dermatologic and gastrointestinal 
AEs (Table 1) (1–3). These events are generally of mild to 
moderate severity and can be relatively easily managed, although 
the cumulative impact on the patient of multiple, concurrent 
mild-to-moderate AEs should not be underestimated. There is 
currently a large body of experience in dealing with the more 
frequent AEs of sorafenib and sunitinib such as hand–foot skin 
reaction (HFSR) and rash, for which prevention and manage-
ment strategies have been established (7). We will examine the 
utility of these strategies in more detail in this review. 
Importantly, a follow up to the phase III TARGET trial has 
demonstrated that no new toxic effects were observed during 
long-term treatment over approximately 3 years with sorafenib 
(8). Indeed, most AEs occurred with early cycles of therapy and 
generally decreased in frequency with each subsequent cycle. 
For sunitinib, treatment for 6 months or more in an expanded 
access program was associated with a higher cumulative inci-
dence of any grade and grade 3–4 AEs compared with treatment 
for less than 6 months, but there was no accumulation of serious 
toxic effects, no increase in grade 3–4 cardiotoxicity, and no new 
or unexpected toxic effects with long-term therapy (9,10). 
Updated safety data from the pazopanib phase III registration 
study (11) showed no significant changes over time in the type, 
Table 1. Most common adverse events reported in European summaries of product characteristics*
Adverse events Sorafenib Sunitinib Pazopanib Bevacizumab + IFN-a Temsirolimus Everolimus
Gastrointestinal disorders      
 Constipation + ++ 2 ++ ++ 2
 Diarrhea ++ ++ ++ ++ ++ ++
 Dyspepsia 2† ++ + 2 2 +
 Dry mouth 2† ++ 2 2 2 +
 Flatulence 2 ++ + 2 2 2
 Glossodynia 2 ++ 2 2 2 2
 Nausea ++ ++ ++ ++ ++ ++
 Oral pain 2 ++ 2 2 + 2
 Stomatitis 2† ++ + ++ ++ ++
 Vomiting ++ ++ ++ ++ ++ ++
Skin and subcutaneous events      
 Acne 2† + 2 2 ++ +
 Alopecia ++ ++ + 2 2 2
 Dry skin ++ ++ + ++ 2 ++
 Erythema ++ + + 2 2 +
 Hair color changes 2 ++ ++ 2 2 2
 HFSR ++ ++ + + 2 +
 Nail disorder 2 + 2 2 ++ +
 Pruritus ++ + + 2 ++ ++
 Rash ++ ++ + 2 ++ ++
 Skin discoloration 2 ++ +‡ ++ 2 2
Infections and infestations      
 Bacterial and viral infections 2 2 2 + ++ ++
Respiratory, thoracic, and mediastinal disorders      
 Cough 2 + 2 2 ++ ++
 Dyspnea 2 + 2 + ++ ++
 Epistaxis 2 ++ + + ++ ++
 Pneumonitis 2 2 2 2 + ++
(Table continues)
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Adverse events Sorafenib Sunitinib Pazopanib Bevacizumab + IFN-a Temsirolimus Everolimus
Cardiac and vascular disorders      
 Ejection fraction decreased 2 ++ 2 2 2 2
 Hemorrhage (including GI, rectal) 2§ 2 2 + + +/2ǁ
 Hypertension ++ ++ ++ ++ + +
Others      
 Allergic/hypersensitivity reactions 2 2 2 2 + ++
 Asthenia/Fatigue ++ ++ ++¶ ++ ++ ++
 Dysgeusia 2 ++ ++# ++ ++ ++
 Headache ++ ++ + ++ 2 +
 Hypothyroidism 2 ++ + 2 2 2
 Insomnia 2 + 2 2 ++ +
 Mucosal inflammation 2 ++ + ++ ++ ++
 Edema 2 ++ + 2 ++ ++
 Proteinurea 2 2 + 2 2 ++
Metabolism and nutrition      
 Anorexia + ++** ++†† ++ ++ ++
 Hypokalemia 2 2 2 + ++ ++
 Hyperglycemia/diabetes mellitus 2 2 2 + ++ ++
 Hypercholesterolemia 2 2 2 2 ++ ++
 Hyperlipidemia 2 2 2 2 ++ ++
Blood and lymphatic system      
 Neutropenia 2† ++ + ++ + ++
 Thrombocytopenia 2 ++ + ++ ++ ++
 Anemia 2† ++ 2 + ++ ++
 Leucopenia 2† + + ++ + 2
 Lymphopenia 2§ + 2 2 + ++
Laboratory abnormalities      
 Blood creatinine increased 2 + + 2 ++ ++
 Increased aspartate aminotransferase 2† + ++ 2 ++ ++
 Increased alanine aminotransferase 2† + ++ 2 + ++
 Bilirubin increased 2 2‡‡ +‡‡,§§ 2 2 ++
* Events reported in ≥10% of patients with RCC treated with any agent (or in patients with different tumor types for bevacizumab). GI = gastointestinal; 
HFSR = hand–foot skin reaction; IFN-a = interferon alpha; ++ = reported at a frequency of ≥10%; + = reported at a frequency of ≥1 to <10%; 2 = not reported 
or reported at a frequency of <1%.
† Reported at a frequency of ≥1 to <10% in studies in multiple tumor types.
‡ Hypopigmentation and depigmentation are listed separately—both reported at a frequency of ≥1 to <10%.
§ Reported at a frequency of ≥10% in studies in multiple tumor types.
ǁ Incidence listed as “not known.”
¶ Fatigue reported at a frequency of >10%; asthenia reported at a frequency of ≥1 to <10%.
# Dysgeusia, ageusia, and hypogeusia.
** Anorexia and decreased appetite.
†† Decreased appetite.
‡‡ The US Food and Drug Administration has added a black box warning for hepatotoxicity in the US labels for sunitinib and pazopanib.
§§ Hyperbilirubinemia.
Table 1 (Continued).
frequency, or severity of AEs; median duration of exposure was 
7.4 months (11).
The range of frequently observed but not necessarily serious or 
life-threatening AEs with the newly licensed TKI pazopanib 
appears to be lower compared with sorafenib and sunitinib (Table 1) 
(12). However, experience with this agent is clearly less extensive, 
and it is possible that different AEs or increased frequency of 
known AEs may emerge with time. For example, with sunitinib, the 
incidence of hypothyroidism was initially reported at 14% (grades 
3–4, 2%) in a phase III clinical trial (3); however, an analysis of 
retrospective and prospective studies suggested that the incidence 
may be greater than 50% (13). It is also important to note that a 
lower frequency of common AEs does not necessarily translate into 
a lower risk of serious or life-threatening AEs (Table 2).
Hypertension is a frequent AE associated with all the TKIs and 
one that can have serious consequences if not properly managed 
(14–16). The optimal monitoring and management of hyperten-
sion is key to successful treatment with these agents and is cur-
rently an area of intense debate (14–16). Cardiovascular events 
such as decline in left ventricular ejection fraction (LVEF), heart 
failure, and QT interval (the time from start of the Q wave to the 
end of the T wave of the cardiac electrical cycle) prolongation have 
also been reported in patients receiving TKIs, although the degree 
of severity differs among agents (Table 1) (2,3).
In terms of life-threatening AEs (Table 2), serious hemorrhage 
is identified as a risk with all three licensed TKIs, and fatal events 
have been recorded during the post-marketing phase for sunitinib 
and during clinical studies with pazopanib (2,3). In addition, a new 
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concern—liver toxicity—has emerged (11). For pazopanib, 
increases in serum alanine transaminase (ALT) occurred in 14% of 
patients and hyperbilirubinemia occurred in 3% of patients; fatal 
hepatotoxicity has also been recorded (2). The US Food and Drug 
Administration (FDA) approved pazopanib with a black box 
warning (a boxed warning regarding the risk of a serious AE that 
may be added to the package insert of a prescription drug) for 
hepatotoxicity (17). The FDA has also added a black box warning 
for hepatotoxicity in the US label for sunitinib (18). With 
sorafenib, transient increases in transaminases and bilirubin were 
also seen in pivotal studies. In post-marketing experience, isolated 
reports have been received consistent with drug-induced hepatitis 
(a potentially life-threatening or fatal condition).
Anti-VEGF Monoclonal Antibody
Although the TKIs and multikinase inhibitors have activity at 
the VEGF receptor, the humanized monoclonal antibody bevaci-
zumab is the only currently available agent that directly targets 
only VEGF. Because bevacizumab is licensed for the treatment of 
a number of different tumors, its safety profile is very well 
described (5). In the treatment of RCC, it is used in combination 
with IFN-a, adding an additional range of AEs to its toxicity 
profile. As with the TKIs, bevacizumab + IFN-a treatment is 
commonly associated with gastrointestinal disorders and general 
AEs such as fatigue and headache. Proteinuria appears to be a 
more “class-specific” AE of bevacizumab + IFN-a treatment, 
occurring at an overall incidence of between 0.7% and 38% across 
clinical trials (5). Some of the most important AEs of bevacizumab + 
IFN-a therapy are gastrointestinal perforation, hemorrhage, and 
cardiovascular events (5). Although these AEs are less common 
than constipation and diarrhea, for example, they can be potentially 
life threatening and should therefore be monitored and managed 
promptly.
mTOR Inhibitors
Everolimus is one of the newer targeted therapies approved for the 
treatment of advanced RCC (6). As a consequence, clinical experi-
ence with this agent is more limited, and its AE profile is less well 
established compared with sorafenib, sunitinib, and bevacizumab. 
However, data from the everolimus expanded access program are 
now becoming available (19). Although temsirolimus is a more 
well-established mTOR inhibitor, there are relatively few real-life 
clinical data on the tolerability of this agent (20).
Because of their immunosuppressive properties, the mTOR 
inhibitors temsirolimus and everolimus are associated with 
treatment-related infections. In addition to general bacterial and 
viral infections, the European summary of product characteristics 
for temsirolimus specifically lists temsirolimus-related pharyngitis, 
rhinitis, urinary tract infections, folliculitis, upper respiratory tract 
infections, and pneumonia (4). In everolimus-treated patients, 
there have also been reports of aspergillosis, candidiasis, and reac-
tivation of hepatitis B (6). Noninfectious pneumonitis is a class 
effect of the mTOR inhibitors. The incidence of pneumonitis in 
patients treated with everolimus or temsirolimus may be higher 
than originally reported in phase II and phase III studies (21–23). 
Retrospective examinations of computed tomography scans 
collected during clinical studies suggest that more than one-quarter 
of RCC patients treated with mTOR inhibitors have evidence of 
pneumonitis (24,25).
The mTOR inhibitors are also the targeted agents most com-
monly associated with disorders of metabolism and nutrition. 
Awareness of these AEs is important because the insidious nature 
Table 2. Potentially serious or life-threatening adverse events reported in European summaries of product characteristics*
Adverse events Sorafenib Sunitinib Pazopanib Bevacizumab + IFN-a Temsirolimus Everolimus
Hematological events 2 U† 2 + 2 2
Infections 2 2 2 2 2 ++†
Pneumonitis 2 2 2 2 +† ++†
Inflammation of the lungs 2 2 2 2 + 2
Pleural effusion 2 2 2 2 + 2
Pericardial effusion 2 2 2 2 U 2
Hepatotoxicity 2 2 +† 2 2 2
Hepatobiliary events 2 U† 2 2 2 2
Pancreatic events 2 U† 2 2 2 2
Renal failure 2 2 2 2 +† 2
GI perforation U U† U† + U 2
Hemorrhage ++ ++ U† + 2 2
Intracerebral bleeding 2 2 U 2 U† 2
Problems with wound healing 2 2 2 ++ + U
VTE events 2 U† 2 2 +† 2
ATE events 2 2 U† + 2 2
Cardiac ischemia/infarction U† 2 U 2 2 2
CV events 2 U† U + 2 2
Hypertensive crisis U 2 2 2 2 2
Hypertensive encephalopathy 2 2 2 U† 2 2
Reversible posterior leukoencephalopathy U 2 2 U 2 2
* Events included under special warnings and precautions or associated with fatal outcomes in the European summary of product characteristics. ATE = arterial 
thromboembolism; CV = cardiovascular; GI = gastrointestinal; IFN-a = interferon alpha; LVEF = left ventricular ejection fraction; VTE = venous thromboembolism; 
++ = reported at a frequency of ≥10%; + = reported at a frequency of ≥1 to <10%; 2 = not included under special warnings and precautions or associated with 
fatal outcomes; U = uncommon, reported at a frequency of <1%.
† Fatal outcomes have been reported.
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of disorders such as hypercholesterolemia and hyperglycemia 
means that symptoms are generally lacking until the condition 
becomes so severe that organ damage occurs. mTOR inhibitors 
also cause fatigue, asthenia, rash, and anemia (26). Because these 
AEs are common among targeted agents, management and coping 
strategies applicable to one agent should be applicable to another.
Review of Management Strategies
Most articles reporting AE management strategies in RCC were 
specific to sorafenib and sunitinib, and there were substantially 
fewer articles related to pazopanib, bevacizumab, temsirolimus, 
and everolimus in this indication. This is to be expected, given that 
sorafenib and sunitinib have been licensed for considerably longer 
than the other targeted therapies, thereby allowing time for their 
AE profiles and subsequent management strategies to become 
established. The specific management strategies identified are 
discussed in the following sections.
Skin and Subcutaneous Adverse Events
A wide range of dermatologic AEs occur with targeted anticancer 
therapies with the frequency of these events varying according to 
the individual targeted agent (overview in Table 1). Rash and 
HFSR are generally held to be the most troublesome side effects 
with sorafenib. However, these side effects are also seen with other 
agents in this class (2,3). Data from the pivotal trial of sorafenib in 
RCC show rash (all grades) occurring in 28% of patients (grade 
3–4 in <1%) (1). HFSR occurred in 19% of patients treated with 
sorafenib and was grade 3–4 in 4%. HFSR is also frequently seen 
in RCC patients treated with sunitinib; the European summary of 
product characteristics gives frequencies of 26% for HFSR (listed 
as palmar–plantar erythrodysethesia) of any grade and 8% for 
grade 3–4 events (3). The frequency of rash with sunitinib (any 
grade, 15%; grade 3–4, <1%) is comparable with that seen during 
treatment with sorafenib (1,3). With pazopanib, HFSR is relatively 
infrequent (any grade, 7%; grade 3–4, 1%), as is rash (any grade, 
9%; grade 3–4, <1%) (2). HFSR is not listed among the undesir-
able effects seen with temsirolimus, although rash and pruritus are 
the most common dermatologic AEs associated with this agent (4). 
In the pivotal phase III trial of temsirolimus, rash (any grade) 
occurred in 42% of patients and was of grade 3–4 severity in 5%, 
whereas pruritus (any grade) occurred in 40% of patients and was 
of grade 3–4 severity in 1% (4). Pruritus is less common with 
sorafenib (all grades, 17%; grade 3–4, 1%), sunitinib (all grades, 
7.4%; grade 3–4, 0.2%), and pazopanib (all grades, 2%) than with 
temsirolimus.
The severity of HFSR can range from minimal skin changes 
(grade 1) to painful ulcerative dermatitis (grade 3), and although 
HFSR is not life threatening, it often results in dose reduction as 
symptoms progress to a degree where they have a detrimental 
effect on day-to-day activities (1,7,27). The published guidance 
identified in the literature search for HFSR can be split into pre-
ventative measures and management strategies (Table 3). Initial 
prophylaxis includes removal of any existing hyperkeratotic areas 
and calluses evident on a pretreatment examination of the palms 
and soles of the feet (71). Such areas can be protected by cush-
ioning and treated with moisturizing creams and keratolytic agents 
such as urea-containing and salicylic acid–containing creams or 
ointments. As an aide-mémoire, this is sometimes referred to as the 
“3C” approach: Control calluses, Comfort with cushions, Cover 
with creams (72). During treatment, care should be taken to 
reduce exposure of the hands and feet to hot water and to avoid 
constrictive footwear, friction, and trauma arising from vigorous 
exercise. Shoes with padded insoles (and possibly also gloves) can 
be worn. There may be benefit in sparingly applying moisturizing 
cream to the hands and feet (28–31). In addition, it is recom-
mended that patients are educated about the visible signs of HFSR 
to aid in the early detection of symptoms (28,30). Management 
strategies for HFSR include topical treatments for grade 1 symp-
toms such as appropriate use of corticosteroids (29,31). Higher 
grades of severity may require dose reduction or interruption of 
the targeted anticancer treatment and in severe or persistent cases, 
discontinuation of treatment (28,29). Nonetheless, to clearly 
define the degree of benefit that can be obtained by using the 
above HFSR prevention and management strategies, there is a 
need for dedicated studies with clear and objective endpoints.
The management strategies that were identified for anticancer 
therapy–related rash include topical therapies for symptomatic 
relief, such as intensified skin care and moisturization, as well as 
application of urea-containing lotion (1,38). However, the long-
term use of topical steroids (eg, betamethasone) is to be avoided 
because it increases the risk of topical infection (33,34). A key 
management issue is to differentiate between nonserious rash 
(usually moderate in intensity, erythematous/squamous, and pos-
sibly diffuse) and serious hypersensitivity rash that can necessitate 
discontinuation of the targeted anticancer drug. The signs that 
suggest the possibility of a serious AE, such as a Drug Reaction 
with Eosinophilia and Systemic Symptoms (DRESS) syndrome or 
a Stevens–Johnson syndrome, include mucosal involvement, bullous 
lesions, and the association with clinical or biological symptoms 
such as elevated temperature, hepatitis, and hypereosinophilia.
An uncommon skin adverse effect (incidence 0.1 to <1%) that 
has been reported with the use of sorafenib, and not with the 
other drugs considered here, is the emergence of actinic keratoses, 
keratoacanthomas, and squamous cell carcinoma, which are 
benign, borderline, and malignant cutaneous neoplasias, respec-
tively (1,40,41). This effect is probably linked to the paradoxical 
activation of the MAPK pathway in keratinocytes by drugs targeting 
Raf proteins because it is also observed, but with a higher 
frequency, in patients treated with more recent and specific v-raf 
murine sarcoma viral oncogene homolog B1 (B-Raf) inhibitors 
(73). Further research is required to understand fully the mechanism 
for cutaneous neoplasia during anticancer therapy. Early recognition 
of these conditions is critical, and patients should be queried about 
the development of any new skin lesions (41). Management of 
these AEs in RCC depends on the clinical situation; however, it is 
recommended that squamous cell carcinomas and keratoacanthomas 
should be surgically removed if possible (40).
Diarrhea
Anticancer treatment–related diarrhea is not only an inconvenient 
AE but can also be life threatening if not sufficiently managed. The 
severity of diarrhea can vary considerably (ranging from mild 
symptoms to fecal incontinence) and have a dramatic negative 
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impact on a patient’s quality of life, as well as physical and 
emotional well-being. In addition to increased bowel movement, 
patients may experience abdominal pain, cramping, proctitis, and 
anal or perianal skin erosion. Some patients may also develop 
aversions to some foods or stop eating, which can lead to weight 
loss, malnutrition, fatigue, and depression (74).
Because diarrhea is one of the most common AEs of anticancer 
therapy (Table 1), there are a number of published clinical guide-
lines for the management of diarrhea in cancer patients (75–78). 
Although these guidelines are not RCC or targeted therapy spe-
cific (and were therefore not uncovered by our search strategy), 
they warrant consideration because they may be beneficial in the 
management of diarrhea associated with the TKIs (27). Guidelines 
suggest that patients should be educated about treatment-related 
diarrhea and encouraged to keep diaries listing episodes, their 
severity, and accompanying symptoms of diarrhea (78); this may 
help clinicians to optimize management strategies.
The management strategies that we identified from the litera-
ture generally fall into four categories: diet, dehydration manage-
ment, pharmacological interventions, and dose adjustments (Table 3). 
Regarding diet, patients are often advised to avoid foods that may 
aggravate diarrhea; they are also encouraged to consume foods 
that may increase the consistency of their stools. Because patients 
can become dehydrated after experiencing particularly long or 
severe episodes of diarrhea, dehydration management is vital in 
these cases. Pharmacological interventions such as loperamide are 
widely used for managing anticancer therapy–related diarrhea; 
however, there is currently no consensus on when during the 
course of anticancer treatment loperamide should be taken. For 
patients who experience grade 3 or 4 AEs, dose adjustments 
in anticancer therapies may be necessary. However, once the 
severity of diarrhea subsides, optimal treatment dosing should be 
reinstated so as not to unnecessarily compromise the efficacy of 
therapy.
Oral or Upper Gastrointestinal Complications
Oral and upper gastrointestinal complications of targeted therapies 
include mucositis, stomatitis, xerostomia (dry mouth), ageusia 
(taste loss), and dysgeusia (taste disturbance) (1–6). Mucositis is 
characterized by painful inflammation and ulceration of the 
mucous membranes lining the digestive tract, whereas stomatitis 
more specifically refers to inflammation of the mucous lining of 
the mouth. Both AEs are associated with pain, which can in turn 
lead to difficulty speaking, eating, or opening the mouth. Stomatitis 
is commonly associated with sunitinib (3,79), bevacizumab + IFN-a 
(5), temsirolimus (4,22), and everolimus (6,80) treatment but is not 
common in patients on sorafenib therapy (Table 1).
Although there are a number of management strategies avail-
able for treating both targeted therapy–related stomatitis and 
mucositis, there is no consensus on which strategy is the most 
effective (Table 3). However, a meta-analysis carried out by 
Worthington et al. (81) assessed the effectiveness of prophylactic 
agents for preventing stomatitis in patients receiving chemotherapy 
(81). Results from their analysis suggest that amifostine, Chinese 
medicine (that involved mixtures of five or 11 herbs including 
honeysuckle flower, licorice root, and magnolia bark), hydrolytic 
enzymes (pepsin, trypsin and chymotrypsin, or wobe-mugos 
preparation of enzymes), and ice chips may be beneficial in pre-
venting or reducing the severity of stomatitis (81).
Xerostomia is commonly associated with sunitinib treatment 
(3,79) but is not commonly related to any of the other targeted 
therapies. Severe cases of xerostomia can cause difficulty in speech 
and eating, can lead to a rise in the number of tooth cavities, and 
can make the mouth vulnerable to infection.
Ageusia and dysgeusia do not generally affect the physical 
well-being of a patient; however, they can both have an impact on 
psychological well-being and the ability of some patients to per-
form tasks associated with daily living (eg, a chef’s ability to work); 
this in turn can have a large negative impact on a patient’s quality 
of life. No recommendations were found from the literature 
on how to treat targeted therapy–related ageusia and dysgeusia; 
however, some studies suggest that zinc replacement, palliative 
measures (eg, use of mints, sugarless chewing gums, and bicarbonate 
mouthwashes), niacin, and vitamin A may help relieve dysgeusia 
(82). In addition, it may be necessary to switch treatments to 
another anticancer drug within the same class to treat severe or 
particularly distressing cases of ageusia and dysgeusia (82).
Anorexia/Weight Loss
Anorexia, which presents as dramatic weight loss, may be caused 
by decreased or a complete loss of appetite that may or may not be 
related to treatment-related nausea, vomiting, oral pain, diarrhea, 
and loss or disturbance of taste. Anorexia-related symptoms, which 
include weakness, fatigue, depression, tooth loss, and organ 
damage, can have a negative impact on health-related quality of 
life, affect a patient’s ability to perform daily tasks, and can result 
in death in severe cases.
Phase III studies of targeted therapies report anorexia occurring 
at a rate of 36% (83), 32% (22), 16% (23), and 22% (12) in patients 
treated with bevacizumab + IFN-a, temsirolimus, everolimus, and 
pazopanib, respectively, and 14% (80) with sorafenib. Although 
anorexia was not reported in the sunitinib phase III trial in meta-
static RCC, anorexia and decreased appetite are reported as 
a combined AE in the summary of product characteristics for 
sunitinib (occurring at a rate of 37.7%) (3).
There are few studies that address the management of targeted 
therapy–related anorexia, which may worsen cachexia in patients 
with RCC (Table 3); however, this topic has been widely addressed 
in several other general publications (84–89). General pharmaco-
logical interventions recommended for treating anorexia and 
cachexia include megestrol acetate (48,87), eicosapentaenoic acid 
diester (86), medroxyprogesterone acetate (88), and mixtures of 
beta-hydroxyl beta-methyl butyrate, glutamine, and arginine (85). 
Other interventions for treating anorexia and cachexia involve 
giving patients simple dietary advice, prescribing artificial saliva, 
mouthwash, and prokinetic antiemetics (84).
Fatigue
Fatigue presents as a distressing, persistent, subjective sense of 
emotional, physical, and/or cognitive tiredness or exhaustion (50). 
Because the etiology of fatigue is often multifactorial—arising as 
an AE of anticancer therapy, as a symptom of the underlying illness, 
and/or as a sign of hypothyroidism, anemia, depression, sleep dis-
turbances, or pain (50)—it is often difficult to manage. However, 
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the initial step is to exclude treatable causes, notably anemia (see 
below), thyroid dysfunction, poor sleep, and depression. Once 
treatable causes have been excluded or managed, the patient may 
be further helped by the teaching of coping strategies.
Cancer-related fatigue is common, occurring in around 75% of 
patients with metastatic disease (50). Targeted therapy–related 
fatigue is also common, occurring in 20% (23) to 51% (90) of 
patients. The frequent occurrence (Table 1) and high impact of 
fatigue on quality of life means that effective management is 
important. However, there is lack of consensus. For example, 
although some sources state that dose modifications in targeted 
therapies are rarely necessary (30), others suggest that for grade 3 
or 4 fatigue, dose modification, or interruption should be consid-
ered (15). Because depression is a common cause of fatigue, anti-
depressants are sometimes considered an option. However, not all 
authors recommend them for reducing the severity of fatigue 
(15,47,50). There is also disagreement on whether patients suf-
fering from fatigue should rest (28,30,50) or maintain everyday 
activities (27,31,38). However, there appears to be agreement that 
patients should be educated and counseled about coping strategies 
because this can motivate them to remain on therapy (28,30,31,38).
Anemia
Anemia is a common but reversible AE of therapy with targeted 
agents, occurring in less than 10% (91) to 91% of patients (23). 
Along with fatigue, symptoms include shortness of breath, paleness 
of the skin, and, in severe cases, heart failure. Anemia and myelo-
suppression may occur particularly with those agents that target 
fms-related tyrosine kinase 3 (Flt-3), such as sunitinib (92).
Hypothyroidism
Hypothyroidism is a very common AE associated with sunitinib 
and is also noted with other agents in the class. The European 
summary of product characteristics reports an incidence of 
hypothyroidism of 14% in patients receiving sunitinib for RCC in 
phase II and phase III clinical trials (3). Results from subsequent 
small clinical studies suggest that the incidence may be higher, 
ranging from 27% to 85% (93–96). The management of hypothy-
roidism is important for controlling associated symptoms such as 
fatigue. Most authors agree that any preexisting hypothyroidism 
should be detected and treated before starting sunitinib treatment, 
as recommended in the European summary of product character-
istics (3). There is less consensus on the extent of monitoring 
required once treatment with sunitinib is in progress. For 
example, Wolter et al. (94) suggest measuring thyroid-stimulating 
hormone (TSH) on days 1 and 28 in the first four cycles of 
sunitinib treatment, arguing that hypothyroidism generally 
develops early during the course of treatment and may be most 
effectively diagnosed with this intensive monitoring. If TSH levels 
remain normal, these authors recommend reducing the frequency 
of monitoring to once every three cycles (on day 28). In contrast, 
Torino et al. (13) propose measurement of TSH on day 1 of every 
cycle of sunitinib treatment (as detailed in Table 3). Although 
measurement of TSH at day 28 of the cycle (at the end of the 
4-week sunitinib treatment period) may increase the chances of 
early detection of thyroid dysfunction, this dysfunction may prove 
to be transient and/or subclinical and not warrant therapy. 
Elevated TSH levels measured on day 1 of the cycle (at the end 
of the 2-week rest period) are more likely to indicate clinically 
relevant thyroid damage requiring further investigation and, if 
appropriate, initiation of corrective therapy (13).
The high incidence of hypothyroidism in patients receiving 
sunitinib raises the question as to whether this is a class effect of 
TKIs. Hypothyroidism was not listed as a common AE in phase III 
studies of either sorafenib or pazopanib (12,83,91); however, the 
European summary of product characteristics for pazopanib notes 
that hypothyroidism was common across RCC phase II and III 
studies (incidence, 4%) (2). A retrospective study of 39 patients 
treated with sorafenib (97) did identify thyroid dysfunction attrib-
utable to the drug in eight (21%) patients, although only two of 
these patients had clinical symptoms requiring treatment (97); a 
prospective study in Japanese patients (98) suggested that hypothy-
roidism may occur more frequently in Japanese than in Western 
patients (98). On the basis of these results, the authors suggested 
that thyroid function tests are warranted before treatment with 
sorafenib (97). Other authors also cite this study (97) as justification 
for extending recommendations for thyroid function monitoring 
to include all patients treated with TKIs.
Hyperglycemia
Hyperglycemia is a very common AE of the mTOR inhibitors 
temsirolimus and everolimus (4,6). In both diabetic and nondiabetic 
patients, it may be prudent to monitor fasting serum glucose 
before initiating treatment with everolimus or temsirolimus and 
periodically thereafter. In diabetic patients, optimization of glycemic 
control is recommended before initiating treatment. Advising 
patients to report excessive thirst or any increase in the volume 
or frequency of urination will help with early identification of 
problems (4,6). Hyperglycemia can be relatively simply treated 
with dietary modifications and an increase in the dose of, or 
initiation of, insulin and/or hypoglycemic agent therapy.
Gastrointestinal Perforation (GIP)
GIP is a rare but potentially fatal complication that has been 
reported in association with all the targeted agents except (to date) 
everolimus (1–5). GIP has been most comprehensively docu-
mented in patients treated with bevacizumab. A meta-analysis (52) 
of 17 randomized studies, including more than 12 000 patients 
with colorectal cancer, breast cancer, pancreatic cancer, non–small 
cell lung cancer, or RCC, reported an overall incidence of GIP of 
0.9% in patients receiving bevacizumab. The relative risk (RR) of 
GIP compared with control subjects was highest in patients with 
colorectal cancer (RR = 3.10, 95% confidence interval [CI] = 1.26 
to 7.63) or RCC (RR = 5.67, 95% CI = 0.66 to 48.42) (52). An 
increased risk was also associated with metastatic disease and with 
a higher dose of bevacizumab (5 vs 2.5 mg/kg). The authors of 
this meta-analysis (52) suggest that to identify patients at high risk 
of GIP, an assessment of the patient’s history should include evi-
dence of past diverticulitis or ulcers, radiation exposure, recent 
sigmoidoscopy or colonoscopy, resection of the primary tumor, 
gastrointestinal obstruction, and multiple previous surgeries.
Patients treated with targeted agents, particularly bevacizumab, 
should be monitored for early signs of GIP. Early diagnosis of 
GIP is complicated by the fact that targeted agents are commonly 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/article-abstract/104/2/93/2517204 by R
adboud U
niversity N
ijm
egen user on 02 M
arch 2020
108   Review | JNCI Vol. 104, Issue 2  |  January 18, 2012
associated with gastrointestinal AEs, and monitoring for signs such 
as fever, abdominal pain, constipation, and vomiting may not be 
sufficient. Further analysis of cases of GIP in patients with RCC 
treated with targeted agents may help to identify more specific 
diagnostic markers. For example, in a report (99) of two patients 
receiving sunitinib for RCC, GIP was observed in association with 
colonic pneumatosis with right-sided colonic involvement, lactate 
elevation, and previous high-dose interleukin 2 exposure (99).
Any case of GIP should result in discontinuation of anticancer 
therapy and appropriate treatment of the perforation. The 
European summaries of product characteristics for bevacizumab 
and sorafenib clearly recommend permanent discontinuation of 
these agents in the case of GIP (1,5). However, in patients who 
were responding to targeted therapy, recovery from GIP and 
appropriate management of the underlying causes may allow 
retreatment, maybe at a reduced dose (52). There are no specific 
recommendations for the management of GIP in patients 
receiving targeted anticancer therapies. Considering the increased 
risk of bleeding and wound-healing complications in patients 
taking VEGF-targeted agents (particularly bevacizumab), nonsur-
gical interventions may be preferable to surgery. A study of 
24 patients with bevacizumab-associated GIP (54) suggested that 
nonoperative treatments, such as placement of a percutaneous 
intra-abdominal catheter, bowel rest, and intravenous antibiotics, 
may be viable options (54). Further studies are warranted to inves-
tigate this possibility, as well as that of subsequent retreatment 
with targeted agents after the occurrence of GIP.
Hypertension
Arterial hypertension is a common AE of inhibitors of the VEGF 
pathway, reported at a frequency of between 12% and 41% in 
patients treated with sorafenib, sunitinib, bevacizumab + IFN-a, 
or pazopanib (1,3,5,12,79,83,91). These incidences may be under-
estimated because they were based on measurements taken at 
predefined visits during clinical trials; more detailed prospective 
evaluation may be necessary to reveal the true incidence of 
hypertension. Management of angiogenesis inhibitor–related 
hypertension (Table 3) is frequently based on the current guide-
lines of the European Society of Hypertension (100) but should be 
optimized on a case-by-case basis.
Prompt diagnosis of hypertension may help to prevent serious 
complications, such as intracranial hemorrhage and heart failure 
(15,16), and maintain patients on treatment for longer periods. In 
this respect, blood pressure (BP) monitoring is clearly important; 
however, there is general disagreement about when and how BP 
should be measured (14,15,31,38,47,56–58). The routine use of 
home BP monitoring may be valuable in standard care for early 
detection and accurate assessment of BP changes (38,47,57,58). In 
a small prospective study (56) in 10 patients treated with sunitinib, 
home measurements based on 24-hour BP monitoring at baseline 
and after 2, 4, and 6 weeks of treatment revealed two cases of 
hypertension that would not otherwise have been detected (56). 
When home monitoring, patients need to be provided with indi-
vidualized thresholds for contacting their health-care provider. 
For example, patients with additional risk factors and rising BP 
may need earlier intervention, even if their BP is within what are 
usually considered to be normal limits (14,56,58).
When it arises, hypertension should be treated promptly as 
needed with standard antihypertensive therapy (appropriate for 
the individual situation of the patient) (1–3,5). Although it is 
generally admitted that angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers (ARB) are useful in 
this indication, no clear recommendation for antihypertensive 
agents can be made because there is a lack of controlled studies 
addressing the treatment of hypertension in patients with RCC. 
Some antihypertensive medications might prove more effective 
in treating anti–VEGF-associated hypertension and be better 
tolerated; in addition, certain antihypertensive medications can 
interfere with antineoplastic activity by modulating VEGF expres-
sion and reducing the antiangiogenic effect of targeted therapies 
(101–103). Large trials (101,102) in patients with diabetic ne-
phropathy clearly indicate that antihypertensives that target the 
renin–angiotensin–aldosterone system have renoprotective effects. 
Both ACE inhibitors and ARB are able to lower the intraglomerular 
pressure independent of any change in systemic BP by dilation of 
the efferent arteriole of the glomerulus. Furthermore, they have 
antiproteinuric effects, which may contribute to protection of 
renal function. However, enalapril and candesartan can inhibit 
myocardial angiogenesis (103).
Because VEGF is known to increase endothelial nitric oxide 
(NO), the hypertensive effect of anti-VEGF compounds is consid-
ered by some to be mediated by the drop in endothelial NO 
synthetase. Antihypertensives that increase endogenous NO 
(eg, nitrates, phosphodiesterase inhibitors, or the beta-blocker 
nebivolol) might be of particular interest and merit evaluation in 
prospective clinical trials (34,104,105). Calcium channel blockers 
(CCBs) may reduce microvascular rarefaction and improve angio-
genesis. In a prospective randomized trial (106) investigating 
approaches to minimizing dose interruptions and reductions of the 
experimental VEGF-targeted agent cediranib, a low dose of CCB 
3–7 days before starting therapy reduced the incidence of severe 
hypertension from 18/63 patients without prophylaxis to 1/63 
patients with prophylaxis (106). However, CCB prophylaxis did 
not result in fewer dose reductions or dose interruptions in cediranib 
therapy. Concerns have been raised over the safety of CCBs, par-
ticularly non-dihydropyridines, because they interfere with 
CYP3A4 activity (15,28,61,103). Thus, dihydropyridines, such as 
amlodipine and nifedipine, may be preferable (103), although 
nifedipine has been shown to induce VEGF secretion (107). 
Diuretics also have been used successfully to manage increases in 
BP arising from cancer treatment; however, thiazide-type diuretics 
should be used cautiously, particularly in patients prone to dehydra-
tion or hypercalcemia (35,58). Results from this literature review 
suggest that further clinical studies are needed to identify optimal 
treatments for managing targeted therapy–related hypertension.
Cardiovascular Events
Of the targeted agents used in RCC, sunitinib is most frequently 
associated with cardiovascular events. Although cardiovascular 
events are not all that common, they can be life threatening and 
thus require careful monitoring (Table 3). Few studies have pro-
spectively examined the cardiotoxicity of TKIs in the treatment of 
RCC with defined cardiac endpoints. Therefore, evidence-based 
recommendations are lacking, and future trials of TKIs and other 
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drugs that affect the VEGF pathway should include careful moni-
toring of cardiac effects. Some such studies are already in progress, 
such as the SWITCH study of sequential use of sorafenib followed 
by sunitinib and vice versa, in which cardiotoxicity will be analyzed 
by means of echocardiography and measurement of N-terminal 
fragment of pro B-type natriuretic peptide (NT-proBNP), with 
a planned interim analysis after 100 patients in each arm have 
completed the study (www.clinicaltrials.gov, NCT00732914).
Generally VEGF-targeted agents should be used with caution 
in any patients with clinically significant cardiovascular disease or 
preexisting congestive heart failure, and these patients should be 
closely monitored for clinical signs of heart failure (3,5). Periodic 
measurement of LVEF using echocardiography, magnetic reso-
nance imaging, or multigated acquisition gives an assessment 
of systolic cardiac function and is the most common method of 
monitoring cardiac function during cancer treatment (108–110). 
However, LVEF alone is not an adequate early marker of cardiac 
damage; other methods to assess cardiac function during cancer 
treatment are being investigated, for example, biomarkers, or 
identification of subclinical changes, such as changes in diastolic 
function (16,62,108–113). Any left ventricle dysfunction could be 
exacerbated or even caused by other AEs such as hypothyroidism 
or hypertension; therefore, these conditions should be carefully 
monitored and managed.
Where targeted agent–related congestive heart failure is 
diagnosed, the treatment strategy is unclear; data on optimal 
therapy are lacking. TKI-induced cardiac dysfunction generally 
responds well to standard heart failure management for nonischemic 
cardiomyopathy, as outlined by the American Heart Association/
American College of Cardiology and the Heart Failure Society of 
America (62). However, because in most cases TKI treatment will 
be withheld, we do not really know if the recovery is attributable 
to the heart failure treatment or to stopping the TKIs. Anecdotal 
reports suggest that left ventricular dysfunction may be at least 
partially reversed on cessation of TKI therapy.
Wound Healing
Bevacizumab has been shown to adversely affect the process of 
wound healing, and the European summary of product character-
istics includes a black box warning recommending treatment dis-
continuation for at least 28 days either side of elective surgery or 
after emergency surgery (5). Signs of wound dehiscence or infec-
tion should be regularly monitored (5,53).
Effects of mTOR inhibitors on wound healing have been docu-
mented (4,6) in the field of transplantation surgery, in which these 
agents are widely used (albeit at a different dose). Impaired wound 
healing was reported as an AE in three (1%) patients during the 
temsirolimus phase III study in RCC. Caution is therefore advised 
when using these agents in patients undergoing surgery; however, 
there are no clear recommendations regarding the optimal dura-
tion of treatment interruption before or after surgery.
Prospective studies have not been conducted on the effects of 
the TKIs sorafenib, sunitinib, and pazopanib on wound healing, 
although one study (114) found that in RCC patients under-
going cytoreductive nephrectomy or resection of retroperitoneal 
recurrence, rates of incision-related complications were similar 
between patients treated with preoperative sorafenib, sunitinib, or 
bevacizumab and those who underwent up-front surgery (114). 
Given the antiangiogenic action of these agents, it is generally 
recommended that treatment be interrupted at least 1 week before 
any scheduled major surgery, with resumption of therapy based on 
clinical judgment of adequate wound healing (1–3). Guidance on 
the necessary duration of treatment interruption is lacking, with 
suggestions ranging from 7 to 14 days (1,3,66). Further studies, or 
further analysis of data obtained during clinical use, are needed to 
better understand the effects of TKIs on wound healing and the 
minimum duration of treatment discontinuation around elective or 
emergency surgery.
Hemorrhagic Events
Minor hemorrhagic events are relatively common in patients 
treated with targeted agents; the most common event reported in 
patients treated with bevacizumab, sunitinib, temsirolimus, and 
everolimus is epistaxis, which usually resolves without medical 
attention (79,83,90,91). Bleeding events with sorafenib in the 
phase III TARGET trial were mostly grade 1 in severity and were 
reported in 15% of patients; rates of severe hemorrhage were sim-
ilar in the sorafenib (3%) and placebo arms (2%) (115). The impact 
of minor bleeding events can be limited by good patient education 
(Table 3) (116).
Life-threatening hemorrhagic events are rarer than minor 
hemorrhagic complications. In the case of bevacizumab, serious 
hemorrhage appears to be more frequently associated with specific 
tumor types such as non–small cell lung cancer or cancer of the 
gastrointestinal tract (5). A point of disagreement is whether 
patients with metastases of the central nervous system (CNS) 
should receive treatment with bevacizumab + IFN-a. A severe 
CNS hemorrhage during a phase I study of bevacizumab (117) led 
to the exclusion of such patients in subsequent clinical trials. As a 
result, there are no data on the use of bevacizumab in this group 
of patients. In contrast, subgroup analyses and case studies have 
indicated that the TKIs sorafenib and sunitinib can be safely 
administered to patients with CNS metastases that have been 
irradiated (9,118–120).
The risk of serious hemorrhage can be minimized by good 
control of hypertension. Clearly, with any agent that increases 
the risk of bleeding, care should be taken in patients who require 
concomitant treatment with anticoagulants, and this is of relevance 
to the problem of prevention of thromboembolic events.
Venous (VTE) and Arterial Thromboembolism (ATE)
VTE is a common complication in cancer patients (65,121). Risk 
factors include age older than 65 years, previous VTE events, and 
surgery (65,121). The role that targeted agents play in modifying 
the risk of VTE is difficult to clarify. Treatment-related VTE, 
including pulmonary embolism and deep vein thrombosis, was 
reported in approximately 2% of patients in clinical studies of 
sunitinib for RCC and in 3% of patients in clinical studies of 
temsirolimus for RCC, including some fatal outcomes (3,4). The 
European summary of product characteristics for bevacizumab 
does not report VTE as a common AE in patients with RCC. 
However, a meta-analysis of 15 studies (122) investigating the 
treatment of various solid tumors with bevacizumab, with or with-
out other antineoplastic agents, suggested that there is an increased 
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risk of VTE in patients who received this agent (122). The overall 
incidence of VTE in patients treated with bevacizumab was 12% 
for all grades and 6% for high-grade VTE, with the highest risk 
reported in patients with non–small cell lung cancer or colorectal 
cancer. The AVOREN phase III study reported an incidence of 
2% of grade 3 or worse VTE in patients with RCC with a relative 
risk of 2.86 (95% CI = 0.62 to 13.24) (83,122).
An increased frequency of ATE has been recorded in multiple 
trials of bevacizumab across tumor types. A pooled analysis (123) 
including 1745 patients from five randomized trials reported an 
overall incidence of 4% of ATE in patients with non–small cell 
lung cancer, colorectal, or breast cancer who received bevacizumab 
combined with chemotherapy and suggested an increased risk of 
ATE associated with bevacizumab (123). The risk of ATE was also 
increased in patients older than 65 years of age and in those who 
had previously experienced an ATE. In the AVOREN phase III 
study, four (2%) patients in the bevacizumab arm had an ATE 
compared with one patient in the placebo arm. ATE such as 
cardiac ischemia and/or infarction occurred in around 3% of 
patients treated with sorafenib or pazopanib in clinical studies of 
RCC patients.
ASCO and American College of Chest Physician guidelines 
provide general recommendations about the prophylaxis and treat-
ment of thrombosis in cancer patients (64,124). Further informa-
tion may be obtained from a recent review of VTE guidelines 
(125). In general, anticoagulation prophylaxis is not recommended 
for ambulatory patients with cancer receiving systemic treatment 
(124); whether the increased risk of thrombotic events with some 
targeted agents warrants prophylaxis in ambulatory patients 
remains unclear. Clearly, acetylsalicylic acid (ASA) or other 
antiplatelet drugs should be used with caution in association with 
anti-VEGF agents because of the increased risk of bleeding. 
A small number of studies suggest that ASA or warfarin can be 
used to control thrombotic complications in patients receiving 
bevacizumab with no significant increase in bleeding events 
(65,121); however, these results are preliminary, and no specific 
recommendations can be made. Further studies are needed to 
better define the balance of risk between thromboembolic and 
hemorrhagic complications.
Pneumonitis
Pneumonitis is a common AE associated with the mTOR inhibi-
tors temsirolimus and everolimus (4,6). A review of cases arising 
during the phase III clinical study of everolimus suggests that the 
risks associated with noninfectious pneumonitis can be effectively 
managed by early recognition and prompt intervention (6,67). 
Because noninfectious pneumonitis in the absence of symptoms is 
not life threatening and does not affect quality of life, it is not 
necessary to routinely monitor patients with chest x-rays or com-
puted tomographic scans. However, patients treated with mTOR 
inhibitors should be carefully monitored for signs and symptoms 
of respiratory illness, which should be rapidly investigated further 
when identified (as outlined in Table 3). The optimal management 
of this AE in patients treated with mTOR inhibitors is not yet 
clearly defined. In clinical practice, use of corticosteroids to 
manage everolimus-associated pneumonitis may be commonplace 
(126); however, initial recommendations from the manufacturer 
suggest that moderate symptoms can be managed with dose reduc-
tions or temporary treatment interruption and that discontinua-
tion of everolimus and initiation of corticosteroid treatment is only 
necessary where severe symptoms are present (6,67).
Concluding Remarks
With the advent of targeted therapies for RCC and their positive 
impact on overall survival, patients are increasingly treated for 
long periods of time, raising challenges in how to manage the 
associated AEs. Multiple toxic effects have been reported with 
targeted agents, some of which differ greatly from those tradition-
ally associated with the cytotoxic agents or immunotherapy. There 
are also some notable differences between the AE profiles of the 
various classes of targeted agents. Dermatologic and gastrointestinal 
AEs are those most commonly reported with TKIs; hypertension 
has also frequently been observed. Bevacizumab + IFN-a is also 
associated with gastrointestinal disorders, in addition to general 
AEs such as fatigue and headache. By contrast, with mTOR inhib-
itors, treatment-related infections, pneumonitis, and metabolic 
disorders are generally the most common AEs.
This review found many articles detailing a large number of 
different investigations for monitoring AEs and interventions for 
AE management, but the supportive evidence for the suggested 
management strategies is generally very weak. Data relating to the 
management of treatment-related AEs are largely anecdotal, and 
there are few consensus recommendations for AE management 
strategies. There is thus an unmet need for systematic evaluation 
of AE monitoring strategies to separate those that are useful 
from those that are not, thereby avoiding subjecting patients to a 
barrage of unnecessary tests.
In this review, we focused on strategies for monitoring and 
managing AEs to avoid dose or drug schedule modifications where 
possible. However, although beyond the scope of this review, an 
assessment of the incidence and consequences of dose modifica-
tions and alternative dose schedules would certainly be worthy of 
further study. For example, sunitinib regimens other than the 
4/2 schedule have entered clinical practice, despite few data on 
their efficacy (127,128).
In conclusion, some suggestions for management of AEs, based 
mainly on expert opinion, can be made. In particular, there are 
clear recommendations for the management of dermatologic and 
oral/gastrointestinal AEs, which are some of the most common 
associated with targeted therapies. This review highlights that 
surprisingly few strong data exist to guide management of side  
effects of these widely used drugs. There is a clear need for system-
atic investigation of management strategies for AEs related to 
targeted therapies for RCC.
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